FGF2 and Alzheimer disease: Our results suggest that, in AD, the lower GAG capacities to bind and activate VEGF165 and FGF-2 might contribute to an altered angiogenic state, and probably to alterations of other neurotrophic processes [42], as neurogenic lineage activation, neuritogenesis and neural plasticity.